Date:3/19/2009

Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Pushability is the amount of force required to push a catheter to a specific depth in the anatomy. Testing completed by Boston Scientific Corp. Data on file. Bench test results may not necessarily be indicative of clinical performance. Twenty-eight percent improvement as compared to Boston Scientific's Atlantis SR Pro catheter.

    CONTACTS:  Paul Donovan
               508-650-8541 (office)
               508-667-5165 (mobile)
               Media Relations
               Boston Scientific Corporation

               Larry Neumann
               508-650-8696 (office)
               Investor Relations
               Boston Scientific Corporation

'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Moodys Raises Boston Scientifics Rating Outlook to Stable
2. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
4. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
5. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
8. Boston Scientific Acquires Labcoat Limited
9. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
10. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
11. Boston Scientific to Participate in Piper Jaffray Health Care Conference